SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549

SCHEDULE 13G (Rule 13d-102)

INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULES 13d-1(b)(c), AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO RULE 13d-2(b)

(Amendment No.) *

KalVista Pharmaceuticals, Inc.				
(Name of Issuer)				
Common Stock				
(Title of Class of Securities)				
483497103				
(CUSIP Number)				
April 27, 2021				
(Date of Event Which Requires Filing of this Statement)				
Check the appropriate box to designate the rule pursuant to which this Schedule is filed:				
□ Rule 13d-1(b)				
⊠ Rule 13d-1(c)				
□ Rule 13d-1(d)				
(Page 1 of 9 Pages)				

* The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

The information required in the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

(a) □ (b) ⊠				
(D) 🗵				
CITIZENSHIP OR PLACE OF ORGANIZATION Delaware				
1,806,037 (1)				
П				
PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9				
7.43%				
TYPE OF REPORTING PERSON*				
PN				
-				

⁽¹⁾ Comprised of shares of common stock held by Deerfield Partners, L.P., of which Deerfield Mgmt, L.P. is the general partner.

	1					
1.	NAME OF REPORTIN					
	I.R.S. IDENTIFICATION NO. OF ABOVE PERSONS (ENTITIES ONLY)					
	Deerfield Management Company, L.P.					
2.	CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP*					
3.	SEC USE ONLY					
4.	CITIZENSHIP OR PL	CITIZENSHIP OR PLACE OF ORGANIZATION				
	Delaware	2017 1000000				
	5.	SOLE VOTING POWER				
NUMBER OF		0				
SHARES BENEFICIALLY	6.	SHARED VOTING POWER				
OWNED BY		1,806,037 (2)				
EACH REPORTING	7.	SOLE DISPOSITIVE POWER				
PERSON		0				
WITH	8.	SHARED DISPOSITIVE POWER				
	0.					
		1,806,037 (2)				
9.	AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON					
	1,806,037 (2)					
10.	CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES* □					
11.	11. PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9					
	7.43% (2)					
12.	TYPE OF REPORTING PERSON*					
	DNI					
	PN					

⁽²⁾ Comprised of shares of common stock held by Deerfield Partners, L.P., of which Deerfield Management Company, L.P. is the investment advisor.

1	NAME OF REPORTIN	IC DEDCONC			
1.					
	I.R.S. IDENTIFICATION NO. OF ABOVE PERSONS (ENTITIES ONLY)				
	Deerfield Partners, L.P.				
2.	CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP*				
			(b) ⊠		
2	CEC LICE ONLY				
3.	SEC USE ONLY				
4.	CITIZENSHIP OR PL	ACE OF ORGANIZATION			
	Dela				
	Delaware 5.	COLE MOZINO DOMED			
	5.	SOLE VOTING POWER			
NUMBER OF		0			
SHARES	6.	SHARED VOTING POWER			
BENEFICIALLY OWNED BY		4.000.007			
EACH		1,806,037			
REPORTING	7.	SOLE DISPOSITIVE POWER			
PERSON WITH		0			
	8.	SHARED DISPOSITIVE POWER			
		1,806,037			
9.	AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON				
Э.	AGGREGATE AMOU	INT DEMERICIALLY OWNED BY EACH REPORTING PERSON			
	1,806,037				
10.	CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES* □				
11.	PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9				
11.	TERCENT OF GENES REFRESENTED DT AWOUNT IN ROW 5				
	7.43%				
12.	TYPE OF REPORTING PERSON*				
	PN				
	* * 1				

	NAME OF DEPORTE	VC DED COVC			
1.	NAME OF REPORTING				
	I.R.S. IDENTIFICATION NO. OF ABOVE PERSONS (ENTITIES ONLY)				
	James E. Flynn				
2.	CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP*				
			(b) ⊠		
3.	SEC USE ONLY	CEC MOD COMM			
3.	SEC USE ONLY				
4.	CITIZENSHIP OR PL	ACE OF ORGANIZATION			
	United States	United States			
	5.	SOLE VOTING POWER			
	5.	SOLL YOUNG TOWLK			
NUMBER OF SHARES		0			
SHARES BENEFICIALLY	6.	SHARED VOTING POWER			
OWNED BY		1,806,037 (3)			
EACH REPORTING	7.	SOLE DISPOSITIVE POWER			
PERSON					
WITH	8.	0 SHARED DISPOSITIVE POWER			
	δ.	SHARED DISPOSITIVE POWER			
		1,806,037 (3)			
9.	AGGREGATE AMOU	NT BENEFICIALLY OWNED BY EACH REPORTING PERSON			
	1,806,037 (3)				
10.		AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES*	П		
101	Children in the state of the st				
11.	11. PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9				
	7.43% (3)				
12.	TYPE OF REPORTING PERSON*				
	TNI				
	IN				

⁽³⁾ Comprised of shares of common stock held by Deerfield Partners, L.P.

CUSIP No.	4	83497103	13G	Page 6 of 9
Item 1(a).	Name	e of Issuer:		
	KalV	ista Pharmaceutica	s, Inc.	_
Item 1(b).	Addr	ess of Issuer's Prin	cipal Executive Offices:	
		ambridge Parkway, oridge, MA 02142	Suite 901E	_
Item 2(a).	Name	e of Person Filing:		
	Jame	s E. Flynn, Deerfie	ld Mgmt, L.P., Deerfield Partners, L.P. and Deerfield Management Company, L.	.P.
Item 2(b).	Addr	ess of Principal Bu	siness Office, or if None, Residence:	
		s E. Flynn, Deerfie NY 10010	ld Mgmt, L.P., Deerfield Partners, L.P. and Deerfield Management Company, 34	45 Park Avenue South, 12th Floor, New
Item 2(c).	Citize	enship:		
	Deer	field Mgmt, L.P., D	eerfield Management Company, L.P. and Deerfield Partners, L.P Delaware lin	nited partnerships;
	Jame	s E. Flynn – United	States citizen	
Item 2(d).	Title	of Class of Securit	es:	
	Comi	mon Stock		
Item 2(e).	CUS	IP Number:		
	4834	97103		
Item 3.	If Th	is Statement is File	d Pursuant to Rule 13d-1(b), or 13d-2(b) or (c), Check Whether the Person Filin	ng is a:
(a)		Broker or dealer r	egistered under Section 15 of the Exchange Act.	
(b)		Bank as defined in	a Section 3(a)(6) of the Exchange Act.	
(c)		Insurance compar	y as defined in Section 3(a)(19) of the Exchange Act.	
(d)		Investment compa	any registered under Section 8 of the Investment Company Act.	
(e)		An investment ad	viser in accordance with Rule 13d-1(b)(1)(ii)(E);	
(f)		An employee ben	efit plan or endowment fund in accordance with Rule 13d-1(b)(1)(ii)(F);	
(g)		A parent holding	company or control person in accordance with Rule 13d-1(b)(1)(ii)(G);	
(h)		A savings associa	tion as defined in Section 3(b) of the Federal Deposit Insurance Act;	
(i)		A church plan tha	t is excluded from the definition of an investment company under Section 3(c)(1	14) of the Investment Company Act;

Deerfield Partners, L.P. - 1,806,037 James E. Flynn – 1,806,037

13G

Page 7 of 9

CUSIP No.

483497103

^{**}See footnotes on cover pages which are incorporated by reference herein.

Item 5. Ownership of Five Percent or Less of a Class.

If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than five percent of the class of securities check the following \Box .

Item 6. Ownership of More Than Five Percent on Behalf of Another Person.

If any other person is known to have the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, such securities, a statement to that effect should be included in response to this item and, if such interest relates to more than five percent of the class, such person should be identified. A listing of the shareholders of an investment company registered under the Investment Company Act of 1940 or the beneficiaries of employee benefit plan, pension fund or endowment fund is not required.

N/A

Item 7. Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.

If a parent holding company or Control person has filed this schedule, pursuant to Rule 13d-1(b)(1)(ii)(G), so indicate under Item 3(g) and attach an exhibit stating the identity and the Item 3 classification of the relevant subsidiary. If a parent holding company or control person has filed this schedule pursuant to Rule 13d-1(c) or Rule 13d-1(d), attach an exhibit stating the identification of the relevant subsidiary.

N/A

Item 8. Identification and Classification of Members of the Group.

If a group has filed this schedule pursuant to ss.240.13d-1(b)(1)(ii)(J), so indicate under Item 3(j) and attach an exhibit stating the identity and Item 3 classification of each member of the group. If a group has filed this schedule pursuant to ss.240.13d-1(c) or ss.240.13d-1(d), attach an exhibit stating the identity of each member of the group.

See Exhibit B

Item 9. Notice of Dissolution of Group.

Notice of dissolution of a group may be furnished as an exhibit stating the date of the dissolution and that all further filings with respect to transactions in the security reported on will be filed, if required, by members of the group, in their individual capacity. See Item 5.

N/A

Item 10. Certifications.

"By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under §240.14a–11."

SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

DEERFIELD MGMT, L.P.

By: J.E. Flynn Capital, LLC, General Partner

By: /s/ Jonathan Isler

Jonathan Isler, Attorney-In-Fact

DEERFIELD MANAGEMENT COMPANY, L.P.

By: Flynn Management LLC, General Partner

By: /s/ Jonathan Isler

Jonathan Isler, Attorney-In-Fact

DEERFIELD PARTNERS, L.P.

By: Deerfield Mgmt, L.P., General Partner By: J.E. Flynn Capital, LLC, General Partner

By: /s/ Jonathan Isler

Jonathan Isler, Attorney-In-Fact

JAMES E. FLYNN

/s/ Jonathan Isler

Jonathan Isler, Attorney-In-Fact

Date: May 7, 2021

Exhibit List

Exhibit A. Joint Filing Agreement.

Exhibit B. Item 8 Statement.

Exhibit C. Power of Attorney (1).

(1) Power of Attorney previously filed as Exhibit 24 to a Form 3 with regard to Proteon Therapeutics, Inc. filed with the Securities and Exchange Commission on August 4, 2017 by Deerfield Special Situations Fund, L.P., Deerfield Partners, L.P., Deerfield International Master Fund, L.P., Deerfield Private Design Fund III, L.P., Deerfield Mgmt III, L.P., Deerfield Mgmt IV, L.P., Deerfield Management Company, L.P., and James E. Flynn.

Exhibit A

Joint Filing Agreement

The undersigned agree that this Schedule 13G, and all amendments thereto, relating to the Common Stock of KalVista Pharmaceuticals, Inc. shall be filed on behalf of the undersigned.

DEERFIELD MGMT, L.P.

By: J.E. Flynn Capital, LLC, General Partner

By: /s/ Jonathan Isler

Jonathan Isler, Attorney-In-Fact

DEERFIELD MANAGEMENT COMPANY, L.P.

By: Flynn Management LLC, General Partner

By: /s/ Jonathan Isler

Jonathan Isler, Attorney-In-Fact

DEERFIELD PARTNERS, L.P.

By: Deerfield Mgmt, L.P., General Partner By: J.E. Flynn Capital, LLC, General Partner

By: /s/ Jonathan Isler

Jonathan Isler, Attorney-In-Fact

JAMES E. FLYNN

/s/ Jonathan Isler

Jonathan Isler, Attorney-In-Fact

Exhibit B

Due to the relationships between them,	the reporting persons hereunder	may be deemed to constit	tute a "group"	with one another f	or purposes of
Section 13(d)(3) of the Securities Exchange Act	of 1934.				